Condition
Cytomegalovirus (CMV) Infection
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
5Total
Early P 1 (1)
P 2 (3)
P 4 (1)
Trial Status
Not Yet Recruiting2
Completed2
Enrolling By Invitation1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07488481Early Phase 1Not Yet RecruitingPrimary
Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission
NCT07379203Phase 2Not Yet RecruitingPrimary
ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse
NCT07009548Phase 4Enrolling By InvitationPrimary
CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients
NCT03940586Phase 2CompletedPrimary
Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)
NCT03629080Phase 2CompletedPrimary
A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients
Showing all 5 trials